LLY vs HUM
Eli Lilly · Humana
| LLY Eli Lilly Healthcare | HUM Humana Healthcare | |
|---|---|---|
| Market | ||
| Price | $1,417.54 +3.19% | $414.50 -0.73% |
| Market cap | $1.33T | $49.8B |
| P/E (TTM) | 48.4 | 38.9 |
| Dividend yield | 0.75% | 0.68% |
| 52-week range | $809.63 – $1,408.38 | $163.11 – $456.50 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Eli Lilly (LLY): Two Drugs Drove 88% Of Growth, EPS Hit By $4.57 R&D Oct 31, 2026 | Humana’s 22% Medicare Advantage Membership Growth Is Being Dismissed As A Liability — The… Jul 10, 2026 |
| Latest earnings | ||
| Reported | Oct 29, 2026 | — |
| Revenue | $24.4 billion +39% YoY | — |
| EPS | $7.22 +7% YoY | — |
| Guidance | Guidance raised | — |
| Revenue growth, last 4 reports | +39% +48% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page | |
Shared topics: Guidance
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.